Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 8/20 | 0.40 |
| ▸ | FEN1 | P39748 | 8/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23649797 | 0.98 | SCN9A (0.45) | SCN9AMCHR1ALOX5APFEN1ACACB | |
| SCHEMBL23649798 | 0.96 | SCN9A (0.44) | SCN9AMCHR1ALOX5APFEN1ACACB | |
| SCHEMBL4268353 | 0.78 | ACACB (0.39) | ACACBMAP4K1LRRK2POLB | |
| SCHEMBL29370636 | 0.78 | EDNRB (0.46) | ACACBMAP4K1LRRK2POLBRAB9A | |
| SCHEMBL12593659 | 0.78 | EDNRB (0.46) | ACACBMAP4K1LRRK2POLBRAB9A | |
| SCHEMBL331710 | 0.77 | — | — | |
| SCHEMBL30842078 | 0.77 | — | — | |
| SCHEMBL17036742 | 0.76 | LRRK2 (0.37) | ACACBMAP4K1LRRK2POLBCCNT1 | |
| SCHEMBL12701660 | 0.76 | LRRK2 (0.37) | SCN9AMCHR1ACACBMAP4K1LRRK2 | |
| SCHEMBL15999342 | 0.76 | RXRA (0.38) | ALOX5APFEN1ACACBMAP4K1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115279771-B | MAP4K1 inhibitors | 缆图药品公司 | 2025-03-21 | — | — | CN | disclosed |
| US-12042495-B2 | MAP4K1 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-23 | — | — | US | disclosed |
| CN-110831600-B | Indole AHR inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2023-10-17 | — | — | CN | disclosed |
| US-20230140954-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230140954-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230140954-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11534441-B2 | MAP4K1 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-27 | — | — | US | disclosed |
| US-11534441-B2 | MAP4K1 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-27 | — | — | US | disclosed |
| EP-4090663-A1 | MAP4K1 INHIBITORS | Blueprint Medicines Corporation (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20220323438-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2022-10-13 | — | — | US | disclosed |
| EP-2768509-B1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2017-03-22 | — | — | EP | disclosed |
| CN-104394869-A | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators | GLAXOSMITHKLINE LLC | 2015-03-04 | — | — | CN | disclosed |
| US-20140349993-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2014-11-27 | — | — | US | disclosed |
| US-20140349993-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2014-11-27 | — | — | US | disclosed |
| US-20140349993-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2014-11-27 | — | — | US | disclosed |
| WO-2013059587-A9 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-10-23 | — | — | WO | disclosed |
| WO-2013059587-A9 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-10-23 | — | — | WO | disclosed |
| CN-104080782-A | Novel imidazole amines as modulators of kinase activity | MERCK PATENT GMBH | 2014-10-01 | — | — | CN | disclosed |
| EP-2768509-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | Glaxosmithkline LLC (US) | 2014-08-27 | — | — | EP | disclosed |
| WO-2013059587-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11534441-B2 | MAP4K1 inhibitors | MAP4K1, MAP4K4, MAP4K2 | SCN9A 1640/4885MCHR1 2903/4885ALOX5AP 4744/4885 |
| US-20220323438-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP4K4, MAP4K2 | SCN9A 1640/4885MCHR1 2903/4885ALOX5AP 4744/4885 |
| US-20140349993-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | SCN9A 3495/4885MCHR1 3729/4885ALOX5AP 2010/4885 |
| US-20230140954-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP4K4, MAP4K2 | SCN9A 1640/4885MCHR1 2903/4885ALOX5AP 4744/4885 |
| US-12042495-B2 | MAP4K1 inhibitors | MAP4K1, MAP4K4, MAP4K2 | SCN9A 1640/4885MCHR1 2903/4885ALOX5AP 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.